Skip to main content

Affymetrix to Provide Karolinska Institutet with Technology for Disease Studies

NEW YORK, Feb. 8 (GenomeWeb News) - The Karolinska Institutet of Swedenhas teamed up with Affymetrix to study gene expression and DNA sequence variation in patients with a number of diseases, the two partners said today.

 

The agreement is part of Affy's translational medicine initiative. Karolinska Institutet, based in Stockholm, will have early access to new microarray technologies from Affymetrix, including the company's Mapping 100K array for high-density genome scans, and will be able to perform studies "at an acceptable cost," according to Jan Carlstedt-Duke, Karolinska's dean of research.

 

Further financial details of the alliance were not provided.

 

Over the next five years, Karolinska researchers plan to study gene expression and genetic variation in patients with atherosclerosis, breast cancer, rheumatoid arthritis, asthma, and dyslexia.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.